NCT06532565 - Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors | Biotech Hunter

Enrollment

154

Participants

Timeline

Start Date

July 26, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions

Advanced Solid Tumors

Interventions

DRUG

GS-2121

Tablet administered orally

DRUG

Zimberelimab

Administered intravenously

Trial Locations (6)

RECRUITING

NEXT Virginia, Fairfax

RECRUITING

NEXT Oncology, San Antonio

RECRUITING

Stanford Cancer Center, Palo Alto

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

The Ottawa Hospital Cancer Centre, Ottawa

RECRUITING

Princess Margaret Cancer Centre, Toronto